Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare company that develops and markets a wide range of human health pharmaceuticals, vaccines, and animal health products. Its human health portfolio includes well-known brands such as Keytruda (cancer immunotherapy), Gardasil (HPV vaccine), Januvia (diabetes), and Lagevrio (COVID-19 treatment). The company also offers vaccines like ProQuad, M-M-R II, Varivax, and RotaTeq. In animal health, Merck provides livestock products under brands like Nuflor, Bovilis, and Revalor, as well as companion animal products such as Bravecto and Sentinel. Additionally, Merck has strategic collaborations, including a development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates and a co-development deal with AstraZeneca for Lynparza.

Merck & Co., Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol MRK. The company trades in US Dollars (USD), reflecting its primary listing in the United States. As a US-based company, its financial reporting and stock price are denominated in USD, making it accessible to investors on major US exchanges.

Merck & Co., Inc. operates in the Healthcare sector and is classified under the Drug Manufacturers - General industry. This means it is primarily involved in the research, development, production, and marketing of pharmaceutical drugs and vaccines for human and animal use. As a drug manufacturer, Merck focuses on creating therapies for a wide range of medical conditions, including oncology, infectious diseases, and chronic illnesses.

Merck & Co., Inc. is headquartered in the United States and serves global markets. As a multinational healthcare company, it operates in numerous countries worldwide, providing human health pharmaceuticals, vaccines, and animal health products. Its products are used in various regions, including the US, Europe, Asia, and other international markets. The company's global presence allows it to address healthcare needs across different populations and geographies.

Merck generates revenue primarily through the sale of prescription pharmaceuticals, vaccines, and animal health products. Key revenue drivers include its oncology drug Keytruda, the HPV vaccine Gardasil, and diabetes treatments like Januvia. The company also earns from veterinary products for livestock (e.g., Nuflor, Revalor) and companion animals (e.g., Bravecto, Sentinel). Additionally, Merck has licensing and collaboration agreements, such as with Daiichi Sankyo for ADC candidates and AstraZeneca for Lynparza, which provide milestone payments and royalties. Its diverse portfolio across human and animal health helps sustain its revenue streams.